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Chorismate mutase catalyzes the conversion of chorismate to prephenate in the
biosynthesis of the aromatic amino acids tyrosine and phenylalanine in bacteria,
fungi and plants. Here, the crystallization of the unusual secreted chorismate
mutase from Mycobacterium tuberculosis (encoded by Rv1885c), a 37.2 kDa
dimeric protein belonging to the AroQ  subclass of mutases, is reported. Crystal
optimization was non-trivial and is discussed in detail. To obtain crystals of
sufﬁcient quality, it was critical to initiate crystallization at higher precipitant
concentration and then transfer the drops to lower precipitant concentrations
within 5–15 min, in an adaptation of a previously described technique [Saridakis
& Chayen (2000), Protein Sci. 9, 755–757]. As a result of the optimization,
diffraction improved from 3.5 to 1.3 A ˚ resolution. The crystals belong to space
group P21, with unit-cell parameters a = 42.6, b= 72.6, c= 62.0 A ˚ ,  = 104.5 .T h e
asymmetric unit contains one biological dimer, with 167 amino acids per
protomer. A soak with a transition-state analogue is also described.
1. Introduction
The biosynthesis of amino acids is an essential process in living cells
as it provides the building blocks for polypeptides and important
primary and secondary metabolites. The shikimate pathway is the
anabolic pathway employed by bacteria, fungi and plants to synthe-
size the aromatic amino acids phenylalanine (Phe), tyrosine (Tyr) and
tryptophan (Trp) (Haslam, 1993). Chorismate mutase (CM; EC
5.4.99.5) is located at the branch point of the shikimate pathway and
channels chorismate into the Tyr/Phe-speciﬁc branch. The enzyme
catalyzes the conversion of chorismate to prephenate, which is
formally a Claisen rearrangement. Chorismate mutases typically
accelerate the uncatalyzed rearrangement by roughly one million-
fold (Andrews et al., 1973). As one of the few enzymes known to
catalyze a pericyclic process, it has generated considerable interest
among enzymologists and bioorganic and computational chemists,
speciﬁcally with respect to the origins of the catalytic efﬁciency
(Andrews et al., 1973; Go ¨risch, 1978; Chook et al., 1994; Haynes et al.,
1994; Wiest & Houk, 1995; Lee, Stewart et al., 1995; Kast, Asif-Ullah
& Hilvert, 1996; Kast, Asif-Ullah, Jiang et al., 1996; Ma et al., 1998;
Mattei et al., 1999; Gustin et al., 1999; Kast et al., 2000; Kienho ¨fer et
al., 2003; Guo et al., 2003; Guimara ˜es et al., 2003; S ˘trajbl et al., 2003;
Zhang et al., 2005).
Structures have been determined for chorismate mutases from
Bacillus subtilis (Chook et al., 1993, 1994; Ladner et al., 2000),
Escherichia coli (Lee, Karplus et al., 1995), Saccharomyces cerevisiae
(Xue et al., 1994; Stra ¨ter et al., 1996, 1997) and the catalytic antibody
1F7 with chorismate mutase activity (Haynes et al., 1994). Recently,
coordinates have also been deposited in the PDB for chorismate
mutases from Thermus thermophilus (PDB codes 1ode, 1ufy, 1ui9)
and Clostridium thermocellum (PDB code 1xho; Xu et al., 2005).
Interestingly, these examples comprise three completely unrelated
folds: while the structurally characterized enzymes from B. subtilis,
T. thermophilus and C. thermocellum have a trimeric pseudo- / -
barrel fold typical of the so-called AroH class of chorismate mutases
(Chook et al., 1994; MacBeath et al., 1998), 1F7 exhibits the char-
acteristic immunoglobulin  -sheet topology. The chorismate mutases
of the AroQ class adopt yet another fold, which is dominated by
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the bifunctional E. coli chorismate mutase-prephenate dehydratase
(also known as EcCM), is an intertwined homodimer that comprises
three  -helices per monomer (Lee, Karplus et al., 1995). This fold has
recently been classiﬁed as AroQ  (O ¨ kvist et al., 2006). The allosteric
yeast chorismate mutase represents the AroQ  subclass (O ¨ kvist et al.,
2006), a more elaborate version of the basic AroQ fold, which shares
weak sequence similarity with EcCM and possesses a structurally
related active-site domain (Xue et al., 1994; Xue & Lipscomb, 1995;
Stra ¨ter et al., 1996, 1997).
A third AroQ subclass, initially known as *AroQ (Xia et al., 1993;
Calhoun et al., 2001; Sasso et al., 2005) and recently classiﬁed as
AroQ  (O ¨ kvist et al., 2006), comprises a group of chorismate mutases
that exhibit convincing sequence similarity to other AroQ sequences
only in the N-terminal moiety (Sasso et al., 2005; O ¨ kvist et al., 2006).
These enzymes are about twice the sizeof theclassical AroQ  domain
and feature a cleavable signal peptide responsible for the export of
these chorismate mutases from the cytoplasm (Xia et al., 1993;
Calhoun et al., 2001; Sasso et al., 2005). It has been speculated that
AroQ  enzymes may play some role in the pathogenicity of its
producer organism (for a discussion and references, see Sasso et al.,
2005). Primary structure comparisons suggested that AroQ  proteins
also have other structural peculiarities (MacBeath et al., 1998; Sasso
et al., 2005). In particular, a critical amino-terminal segment carrying
a conserved active-site arginine is lacking in AroQ  chorismate
mutases. Instead, a homologous helical segment is present in the
middle of the polypeptide chain, indicating that the structure of the
exported AroQ  proteins must be topologically distinct from those of
the other known AroQ prototypes (Sasso et al., 2005). To investigate
this issue and to gain insights into the structure–function relationship
of these enzymes, which have the potential to serve as formidable
speciﬁc drug targets, we have set out to determine the high-resolution
crystal structure of the secreted chorismate mutase from the model
pathogen Mycobacterium tuberculosis (*MtCM; encoded by open
reading frame Rv1885c in strain H37Rv), which represents the ﬁrst
characterized example of an AroQ  fold (O ¨ kvist et al., 2006).
However, crystallization of this enzyme turned out to be non-
trivial. While small well ordered crystals could readily be obtained
within less than half an hour of setting up the drops, it seemed
impossible to obtain (fewer and) larger crystals with better diffraction
quality. Common strategies to increase crystal size are to lower the
precipitant or protein concentration, thereby moving in the phase
diagram from a condition of high supersaturation (where nucleation
occurs) to a concentration of lower supersaturation (thus reducing
the number of spontaneously formed nuclei, but still staying within
the ‘labile’ zone where nucleation can occur; Mikol & Giege ´, 1992).
Another well known factor that can inﬂuence nucleation is the
temperature, which has an impact both on the phase diagram itself
and on equilibration kinetics. As an alternative to temperature
variation, the equilibration time might be inﬂuenced more predic-
tably by applying a layer of oil on top of the reservoir of a vapour-
diffusion setup (Chayen, 1997). In this way, equilibration is slowed
down, warranting controlled entry into the ‘labile’ nucleation zone.
All of these protocols work relatively well if the nucleation rate
increases gradually upon increasing precipitant or protein concen-
tration. However, if instead there is an abrupt increase in nucleation
rate, it can be very difﬁcult to hit the point optimal for both
nucleation and crystal growth (if such a point exists at all). In these
cases, the application of seeding techniques may be attempted (Stura
& Wilson, 1992; Stura, 1999), which approach the problem from the
opposite end by placing crystal nuclei in the form of small seeds into
the metastable zone optimal for crystal growth. Finding conditions
appropriate for seeding has its own inherent difﬁculties, however, as
the metastable zone can be rather narrow and excursions to either
side of the phase diagram will inevitably result in either extensive
secondary nucleation or dissolution of the seeds. If only little protein
is available, this adds to the challenge. A few years ago, two new
approaches to the problem were described (Saridakis et al., 1994;
Saridakis & Chayen, 2000). The ﬁrst method involves diluting
microbatch drops after incubating them for several hours under
spontaneous nucleation conditions (Saridakis et al., 1994), while the
second approach relies on transferring cover slips of hanging-drop
vapour-diffusion setups from nucleation conditions to the metastable
zone (Saridakis & Chayen, 2000). In the present report, we describe
the crystal optimization of a protein target that crystallizes very
rapidly and show that this problem can be solved by adapting the
approach by Saridakis & Chayen (2000) to very short crystallization
times.
2. Experimental procedures, results and discussion
2.1. Crystallization
Two different protein batches were used for crystallization. In both
cases, recombinant *MtCM was prepared from E. coli strain KA29 as
described in Sasso et al. (2005) and concentrated to 10–20 mg ml
 1.
Immediately prior to crystallization setups, the protein solutions were
centrifuged at 10 000 rev min
 1 for 10 min at 277 K in order to spin
down any ﬂoating particles and aggregated insoluble protein. Stan-
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Figure 1
(a) Photograph of *MtCM crystals obtained straight from initial screens (crystal
size  20 mm). (b) Photograph of *MtCM crystals from optimized crystallization
conditions (crystal size  1 mm in the longest dimension).dard initial crystallization tests were then performed by the hanging-
drop vapour-diffusion method in 24-well tissue-culture plates
(Go ¨teborgs Termometerfabrik, Sweden) using siliconized glass cover
slips from Hampton Research (CA, USA).
For the ﬁrst crystallization trials, we used a 175-residue version of
*MtCM (encoded on plasmid pKTU3-HCT) devoid of the cleavable
signal peptide but containing a C-terminal His tag (Sasso et al., 2005).
The protein sample (12.6 mg ml
 1)was dissolved in 20 mMpotassium
phosphate buffer pH 7.5. Structure Screen 1 (Molecular Dimensions
Ltd, England) gave a few leads, which were optimized, with the best
preliminary condition consisting only of 15% PEG 8000 (without
buffer). In order to explore different conditions which were not
limited by the use of phosphate as buffer, we then switched to protein
(18.6 mg ml
 1) buffered with 20 mM Tris–HCl pH 8.0. This time, the
leaderless untagged 167-residue version of *MtCM encoded by
plasmid pKTU3-HT was used (Sasso et al., 2005). The ﬁrst screen at
room temperature (293 K) gave a hit for condition No. 18 (0.2 M
sodium acetate, cacodylate pH 6.5, 30% PEG 8000). A shower of
small, well shaped and strongly birefringent single crystals appeared
within 20 min of the ﬁrst crystallization setup (Fig. 1a). These crystals
diffracted to 3–4 A ˚ resolution. Subsequently, an intense effort was
invested into optimizing the crystallization conditions and particu-
larly into slowing down crystallization in order to obtain fewer but
larger crystals. However, none of the modiﬁcations, such as lowering
the protein or precipitant concentration, changing the volume ratios
and temperature, using additives or layering the reservoirs with
various oils etc.,proved successful: we either still obtained a shower of
small crystals within 20 min of setting up the drops (using a reservoir
concentration of  20% PEG) or we did not obtain any crystals at all.
Even seeding did not help. The ﬁnal breakthrough came when we
recalled a publication by Saridakis & Chayen (2000) in which
nucleation was initiated at a high precipitant concentration (which is
more likely to produce nucleation centres) followed by transferring
the drops before crystals became visible macroscopically to reservoirs
with a lower precipitant concentration (which is favourable for crystal
growth). In our case, crystallization times were extremely short, so
the drops needed to be transferred within less than 20 min. After
initial tests showed dramatic improvements upon implementing this
strategy, we adopted a more systematic approach and devised a grid
screen in which both the incubation period before transfer and the
concentration of the ﬁnal reservoir solution were varied. The best
results were obtained when suspending the drops (1.5 ml protein +
1.5 ml reservoir solution) over a starting reservoir (1 ml) containing
20% PEG 4000 (in addition to 0.2 M sodium acetate and cacodylate
buffer pH 6.5) and then transferring them after 5–15 min to reservoirs
containing only 5–15% PEG 4000 (other ingredients constant). In this
way, huge crystals ( 1 mm in the longest dimension) appeared
overnight which did not look perfect but diffracted to beyond 1.6 A ˚
resolution (Fig. 1b). In general, lower reservoir concentrations and
shorter incubation times coincided with fewer (and larger) crystals,
with the reservoir concentration having the larger impact (particu-
larly for concentrations of <10% PEG).
To our knowledge, this is the ﬁrst time that the technique of
Saridakis & Chayen (2000) has been applied to such short crystal-
lization times. Obviously, in time spans as short as a few minutes,
equilibration with the reservoir solution cannot occur. Nevertheless,
it turned out to be critical for our experiments to initiate crystal-
lization at a PEG concentration of 20% (before transferring the drop
to lower concentrations). The reason for this is presumably a rather
steep concentration gradient of PEG in the drop immediately after
pipetting the reservoir solution onto the protein droplet. In the
mixing zone at the interface between protein and precipitant solution,
the PEG concentration will be very close to 20%, enabling the
formation of crystal nuclei (‘shock’ nucleation). The locally high PEG
concentration will subsequently decrease by diffusion, establishing
conditions favorable for crystal growth, provided that the vapour
pressure from the reservoir is sufﬁciently high to prevent rapid
dehydration of the drop, thus avoiding further nucleation.
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Figure 2
Diffraction image from a *MtCM crystal recorded at beamline ID14-4, ESRF, Grenoble. Resolution rings are indicated in (a) and a close-up view of the outer rings (b) shows
that the crystal diffracts to a maximum resolution of 1.3 A ˚ (see encircled reﬂection in outer resolution ring).2.2. Preparation of a transition-state analogue inhibitor complex
In order to localize and investigate the active site of *MtCM, we
performed soaks of the unliganded protein crystals in a solution
containing an endo-oxabicyclic dicarboxylic acid (referred to here as
‘TSA’; Bartlett & Johnson, 1985; Bartlett et al., 1988). This compound
is known to be an excellent mimic of the geometry of the transition
state of the chorismate mutase reaction and is currently the best
inhibitor for a broad range of chorismate mutases (Mandal & Hilvert,
2003), including *MtCM(Sasso et al., 2005). Consequently, ithas been
used as a ligand in many structural studies of chorismate mutases
(Chook et al., 1993, 1994; Haynes et al., 1994; Lee, Karplus et al., 1995;
Stra ¨ter et al., 1997).
Two different soaking techniques were tested. In order to minimize
consumption of the precious compound, we ﬁrst tried to dissolve a
tiny amount of solid TSA directly in a drop containing *MtCM
crystals. However, all crystals in the drop dissolved immediately. We
then took 0.5 ml of this TSA-containing drop and added it to a 1.5 ml
drop containing more *MtCM crystals. After 20 min soaking time, the
crystals were cryoprotected by pipetting a drop of mother liquor
containing 10% PEG 400 on top of the soak. Thereafter, the crystals
were ﬂash-frozen in liquid nitrogen and stored for data collection.
Crystal structure analysis (O ¨ kvist et al., 2006) conﬁrmed the presence
of TSA in the active site of *MtCM.
2.3. X-ray diffraction analysis
X-ray data were collected and processed as reported by O ¨ kvist et
al. (2006). *MtCM crystals diffracted to beyond 1.6 A ˚ resolution
(diffraction limit 1.3 A ˚ resolution; Fig. 2 and Table 1) and belong to
the monoclinic space group P21, with unit-cell parameters a = 42.6,
b = 72.6, c = 62.0 A ˚ ,   = 104.5  for the free enzyme and a = 42.9,
b = 72.8, c = 61.7 A ˚ ,   = 104.0  for the TSA complex. The Matthews
parameter VM is 2.9 A ˚ 3 Da
 1 (Matthews, 1968; calculated for a unit
cell containing two protomers per asymmetric unit), which corre-
sponds to a solvent content of 57%. The dimeric nature of *MtCM is
consistent with previous biochemical data (Sasso et al., 2005; Prakash
et al., 2005). Since sequence alignments (Sasso et al., 2005) suggested
homology to the E. coli AroQp domain, phasing was attempted by
molecular replacement using the E. coli structure (PDB code 1ecm;
Lee, Karplus et al., 1995) as a search model. However, even
exhaustive trials did not yield a solution to the problem. A probable
reason for the failure is the relatively poor overall sequence
homology (16% identity, according to BLASTP v.2.2.6 from NCBI;
Altschul et al., 1997) between the entire 167-residue *MtCM poly-
peptide and the structurally characterized 109-residue E. coli AroQp
domain, together with signiﬁcant structural differences of the C-
terminal helices (O ¨ kvist et al., 2006).
We have therefore prepared heavy-atom derivatives (Pb
II acetate
and Tl
III acetate soaks) and solved the structure by the MAD phasing
technique based on the Pb
II derivative (O ¨ kvist et al., 2006).
3. Concluding remarks
While crystallization of the same protein has been reported very
recently by another group (Qamra et al., 2005), our results are distinct
since the crystal forms are different (space group P21 instead of C2)
and we have signiﬁcantly higher resolution data ( 1.6 A ˚ versus
2.1 A ˚ ). Furthermore, we describe the crystallization of free enzyme
and a soak with a transition-state analogue, while Qamra and
coworkers cocrystallized *MtCM with l-tryptophan.
In addition, this report addresses in detail a general and very
challenging crystallization problem and its subsequent solution,
which led to the development of an empirical method for crystal
optimization for cases with short crystallization times. By applying
the optimized protocol, the diffraction limit of the *MtCM crystals
could be extended from  3.5 to 1.3 A ˚ . This technique, which involves
the transfer of crystallization drops to lower concentration reservoirs
(varying both reservoir concentration and incubation time before
transfer), is particularly useful if the protein of interest crystallizes in
a narrow window of conditions and only little protein material is
available.
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